Andrew Hill Investment Advisors Inc. Has $212,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Andrew Hill Investment Advisors Inc. cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 80.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 512 shares of the company’s stock after selling 2,155 shares during the quarter. Andrew Hill Investment Advisors Inc.’s holdings in IDEXX Laboratories were worth $212,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Hurley Capital LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth $29,000. Rialto Wealth Management LLC purchased a new position in IDEXX Laboratories in the fourth quarter worth approximately $30,000. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $31,000. Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth about $38,000. Finally, Crews Bank & Trust bought a new position in IDEXX Laboratories during the 4th quarter worth approximately $41,000. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Morgan Stanley decreased their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Bank of America increased their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, April 4th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Trading Up 10.0 %

Shares of NASDAQ:IDXX opened at $397.10 on Thursday. The company has a market capitalization of $32.18 billion, a PE ratio of 37.22, a PEG ratio of 3.41 and a beta of 1.50. The business has a 50 day moving average of $431.26 and a two-hundred day moving average of $435.73. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.